Hepatitis and Blood Transfusion: Safety, Screening, and Recipient Guidance

Modern blood supply safety has virtually eliminated transfusion-transmitted hepatitis in developed nations.

Current Screening (U.S./FDA)

  • Hepatitis B: HBsAg + anti-HBc + HBV NAT (nucleic acid testing) – window period ~10–15 days.
  • Hepatitis C: Anti-HCV + HCV NAT – window period ~1–2 weeks.
  • Hepatitis E: Not routinely screened (low prevalence in US); emerging concern in Europe.
  • Donor screening: Risk behavior questionnaire, travel deferrals, ALT (historical).

Residual Risk Estimates (U.S.)

  • HBV: ~1 in 1–2 million units
  • HCV: ~1 in 2–4 million units
  • HIV: ~1 in 2–3 million units

For a Hepatitis-Positive Recipient

  • You CAN receive blood transfusions. Your hepatitis does not contraindicate receiving screened blood products.
  • Indications unchanged: Same thresholds (Hb 7–8 g/dL, symptomatic, etc.).
  • Special considerations:
    • Chronic HBV/HCV: Monitor liver function; avoid hepatotoxic drugs; coordinate with hepatology.
    • Acute hepatitis: Transfuse only if life-threatening anemia; avoid volume overload.
    • Post-transplant immunosuppression: May need CMV-negative, irradiated products.

If You Were Infected *By* Transfusion (Historical)

  • Pre-1992 (HCV) or pre-1975 (HBV) recipients should be tested.
  • Lookback programs notify recipients of positive donor retesting.
  • Compensation programs exist in some countries (e.g., UK, Canada, Japan).

Bottom line: Current blood supply is extremely safe. Having hepatitis does not preclude receiving transfusions. Discuss with your hematologist/hepatologist for individualized plan.

Blood Disorders - Related Articles